The companies announced a long-term collaboration to make obesity treatments more affordable, they said on Tuesday.

Researchers in Dallas want to know if the class of drugs, GIP/GLP-1 receptor agonists, might be a secret weapon in the fight ...

Eli Lilly ( LLY 2.92%) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a ...

UB researcher Nicole Albanese talks about recent developments, including the end of the shortage of weight-loss drugs and the ...

As the FDA cracks down on compounded GLP-1 drugs like semaglutide and tirzepatide, the market for GLP-1 supplements is taking ...

Wegovy and Zepbound, the two leading weight-loss drugs, together sold less than $5 billion in 2023, according to ...

All these drugs are very effective and they’ve become a game changer for people who need to lose weight. Get on the drug, eat ...

The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.

A daily weight loss pill being tested by Eli Lilly could work as well as its GLP-1 injection counterparts like Ozempic, ...

Researchers at the Pennington Biomedical Research Center conducted a first-of-its-kind study to provide insights into the ...

A pair of studies show that Zepbound can help adults with obesity and overweight achieve sustained and meaningful weight loss. Some groups saw more pronounced effects than others.

Eli Lilly ( NYSE: LLY) has filed lawsuits against four telehealth platforms that the pharma giant alleges are selling ...